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BACKGROUND: Our objective was to analyse the cost effectiveness of computed tomography (CT) screening for lung cancer in terms
of the cost per long-term survivor, which has not been evaluated to date.
METHODS: Estimations were computed based on data from the Surveillance, Epidemiology, and End Results registries covering years
1999–2003. The design framework of our model allowed for the incorporation of multiple values taken from the epidemiological
and clinical literature to be utilised for cost inputs, scope of patients screened, diagnostic staging, and survival percentages applied
separately to two cohorts: age 40–79 and 60–79 years. This enabled the analysis of over 1400 scenarios, each containing a unique
set of input values, for which the estimated cost per 5-year survivor (CP5YS) was compared between the symptom-detected and
proactive screening approaches.
RESULTS: Estimated CP5YS were higher for the symptom-detected approach in all 729 scenarios analysed for the cohort ages
60–79 years, ranging from approximately $5800 to $116700 increased cost per 5-year survivor (CP5YS). For the cohort ages
40–79 years, 75% of the 729 scenarios analysed showed increased CP5YS for the symptom-detected approach ranging from $5700
to $110000 increased CP5YS. Total costs and total 5-year survivors were higher for the proactive screening method for all scenarios
analysed across both cohorts with increases ranging from 50–256% and 98–309%, respectively.
CONCLUSION: The predicted increase in long-term survival with CT screening and the potential for better utilisation of health-care
dollars in terms of CP5YS, particularly when screening patients over the age of 60 years, are critically important considerations in
directing effective future lung cancer management strategy.
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Lung cancer is the leading cause of cancer deaths nationwide. An
estimated 162000 people would have died of lung cancer in the
United States in 2006 (American Cancer Society, 2006). Currently,
only 16% of lung cancers are diagnosed when the disease is still
localised and the 5-year survival for all stages combined is 15%
(Jemal et al, 2005).
Because lung cancer is seldom symptomatic in early stage and
treatment in advanced stage has very low survival (Mountain,
1997), current research has focused on methods to detect lung
cancer at an earlier stage where curative treatment can be offered.
Results from the International Early Lung Cancer Action Project
(I-ELCAP) demonstrating striking improvement in early stage
detection of lung cancer by low-radiation-dose computed tomo-
graphy (CT) screening (Henschke et al, 1999; Henschke et al, 2001)
have sparked debate on the cost-effectiveness of a CT screening
programme, with widely variant results reported (Marshall et al,
2001a; Marshall et al, 2001b; Chirikos et al, 2002; Mahadevia et al,
2003; Wisnivesky et al, 2003). In a systemic review published in
January 2006 (Black et al, 2006), the authors conclude that many
issues remain unresolved in the debate over the true cost-
effectiveness of lung cancer screening programmes. Attention to
this issue has further escalated following the reported results of
over 30000 persons screened in the large collaborative I-ELCAP
study, which concluded that annual spiral CT screening can detect
lung cancer that is curable in most cases (Henschke et al, 2006a).
In addition, an analysis of the mean sojourn time and sensitivity
of CT screening for lung cancer estimated approximately 23%
mortality reduction possible by an annual CT screening pro-
gramme opposed to observation (Chien and Chen, 2008). Knudsen
et al (2007) have emphasised the need for mathematical models
that examine the cost effectiveness of implementation of popula-
tion CT screening.
Many investigations of cancer treatment cost-effectiveness
utilise quality-adjusted life year (QALY) as the primary metric to
measure the results of interventions that provide some improve-
ment in quality and/or duration of life, but only for limited
periods of time. For example, a cancer treatment that results in
improvement in duration of survival by 3 months at cost of $25000
would result in a cost per year or QALY of approximately $100000,
as it requires four patients, each experiencing a 3-month
improvement in survival to add up to a year of life gained.
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sAlthough this metric has the advantage of wide utilisation, in
a certain sense, it is a misleading figure, as in this example no
single patient would actually survive 1 year. Preventive screening
measures, where the positive impact on health outcomes may
not be measurable for many years, may be difficult to quantify
using QALYs (Phillips and Thompson, 2003). Arguably, the most
important consideration in determining cost effectiveness for
differing approaches to lung cancer is the number of long-term
survivors attained by a given strategy. Accordingly, we believe that
the cost of a long-term survival is more meaningful to the reader,
and is particularly more important to patients at high-risk of
lung cancer. The purpose of this study is to evaluate the estimated
cost-effectiveness of a proactive screening programme compared
with current lung cancer strategies when applied to a representa-
tive subset of the US population. We compared the ratio of 5-year
survivors to the total screening, diagnosis, and treatment costs for
the current management algorithm that we will designate as the
symptomatic tumour identification (STID) approach and for an
early detection approach using CT screening (EDCTS). Second, we
report the estimated total costs and total 5-year survivors
associated with each strategy. The EDCTS protocol is based on
I-ELCAP recommendations (Henschke, 2006). We separately
applied this analysis to two cohorts distinguished by age. One
cohort was in the age of 40–79 years and the second cohort was in
the age of 60–79 years.
MATERIALS AND METHODS
We constructed a mathematical model based on multivariate
analysis of empirical data to estimate the ratio of screening,
diagnosis, and treatment costs per 5-year non-small-cell lung
cancer (NSCLC) survivor for two different lung cancer manage-
ment strategies, STID and EDCTS. These estimations were
computed in 2005 USD based on the most recent 5 years of data
available, extending from 1999 to 2003, within the 13 Surveillance,
Epidemiology, and End Results (SEER) data registries (National
Cancer Institute, 2005). With respect to selected demographic and
epidemiologic factors, these areas are a reasonably representative
subset of the US population (Ries et al, 2005). The scope of our
analysis covered a population of approximately 15 million people.
The design framework of our model allowed for the incorporation
of multiple values taken from the epidemiological and clinical
literature to be utilised for cost inputs, scope of patients screened,
diagnostic staging, and survival percentages. This methodology
enabled the analysis of over 700 scenarios for each of the two
cohorts (for a total of over 1400 scenarios), each containing a
unique set of input values. For each of these scenarios, the estimated
CP5YS was compared between the STID and EDCTS approaches. By
analysing a broad range of parameter values, we were able to
evaluate the sensitivity of selected variables by using a range of
favourable and unfavourable estimates. In addition, this study
design also enabled the evaluation of completely separate parameter
estimates and calculations from different sources of published data.
Our model assumes that the capital equipment and resources
necessary for both management strategies are already in place.
Input variables and source data
Population screened. The initial I-ELCAP screening study pub-
lished in 1999 screened at-risk persons aged 60 years or
older (Henschke et al, 1999). The subsequent large collaborative
I-ELCAP study published in 2006 screened at-risk persons aged 40
and older (Henschke et al, 2006a). Approximately 98.3% of the
31567 persons screened in the large collaborative I-ELCAP study
were under the age of 80 years. As such, we analysed two separate
cohorts: one cohort was of the age 40–79 years and the second
cohort was of the age 60–79 years. The population screened for
lung cancer in our analysis was based on inclusion criteria from I-
ELCAP reported studies, which screened patients with a history of
at least 10 pack-years of cigarette smoking, no history of cancer
(other than non-melanoma skin cancer), and who were fit to
undergo thoracic surgery (Henschke et al, 1999). We estimated
this population using the following steps:
First, we determined the total population per the 13 SEER data
registries from 1999–2003 for each of the two cohorts. This total
population was reduced by 0.45% to reflect the incidence of cancer
other than non-melanoma skin cancer per the SEER Cancer
Statistics Review (Ries et al, 2005).
Second, we estimated the percentage of US adults in each cohort
with at least a 10 pack-year history of smoking, regardless of
current smoking status, using figures reported by the 2003
National Cancer Institute and Centers for Disease Control and
Prevention Co-sponsored Tobacco Use Special Cessation Supple-
ment to the Current Population Survey (CPS) (National Cancer
Institute, 2003). To evaluate the sensitivity of this parameter and
incorporate a range of variability in actual smoking history, a 10%
increase/decrease in the CPS percentage was also analysed as
upper and lower bound estimates, respectively (Table 1).
We then estimated the percent of this population that would be
unfit for surgery by using SEER data to determine the percent of
stage I tumours diagnosed in patients aged 40–79 and 60–79,
respectively for each cohort, in whom surgery was not recom-
mended or was contraindicated (Criteria: lung and bronchus
NSCLC, invasive, microscopically confirmed, the patient’s first
primary cancer, and diagnosed between 1999 and 2003. Cases
where surgery was recommended and the patient refused the
procedure were counted the same as cases where surgery was
performed. Cases where it was unknown whether surgery was
recommended were omitted from the analysis). This resulted in an
estimate of 14.7% for the cohort ages 40–79 years who are
excluded from screening because they would not be fit for surgery
and 17.0% for the cohort ages 60–79 years. It is important to
emphasise that some individuals who would not be the candidates
for standard surgical procedures might still receive potentially
curative treatment with minimally invasive surgical approaches,
radiation therapy, radiofrequency ablation, or other methods.
Using steps (1), (2), and (3) described above, we quantified an
estimate of the total population that would be eligible for screening
in each cohort in accordance with I-ELCAP inclusion criteria, with
an upper and lower bound estimate for the percent of the
population with a 10 pack-year history of smoking (Table 1).
Statistics on compliance with breast cancer screening guidelines
from three separate studies (Horton et al, 1996; Phillips et al, 1998;
Rahman et al, 2003) were used to estimate the compliance with
lung cancer screening recommendations (Table 1). Multiplying the
SEER population meeting the inclusion criteria by the estimated
compliance percent provides estimates of the total population that
would receive the screening procedures (Table 2).
The choice of different inclusion criteria (e.g., older age at entry,
or higher/lower pack-years requirement) would result in changes
in number of individuals screened, costs, and results.
Baseline screening vs annual repeat screening. In the I-ELCAP
studies, the percentage of patients requiring additional tests
subsequent to the initial CT scan was different in the first year
(baseline screen) than in annual repeat screening. In addition, the
percent of cases where malignancy was found was also different for
baseline screens vs annual repeat screens (Henschke et al, 1999;
Henschke et al, 2001; Henschke et al, 2006a). For the purpose of
our estimation of screening costs and malignancies detected, the
‘Population Screened’ described above for each year was divided
into groups reflecting those receiving a baseline screen vs those
receiving repeat annual screens. This was carried out based on the
large collaborative I-ELCAP study, in which 31567 persons
received a baseline screen with 27456 (87.0%) following up with
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san annual repeat screen (Henschke et al, 2006a). This reflects a
dropout rate (i.e., the percent of patients who receive a baseline
scan and do not follow up with annual repeat scans) of 13%. This
information was used to estimate baseline and repeat screens as
follows: (1) in year one, all screens are baseline screens; (2) in all
subsequent years, 87.0% of the patients screened in the earlier year
Table 1 Summary of input variables and source data
a
Parameter values Source
Input 1 Input 2 Input 3 Input 1 Input 2 Input 3
Percent of US adults with a 10 pack-year smoking history %
Age 40–79
b 28.4 31.3 25.6 NCI (2003) Estimate Estimate
Age 60–79 32.3 35.5 29.1 NCI (2003) Estimate Estimate
(A) (B) (C)
Compliance with screening
recommendations (%)
47.4 27.0 41.4 Horton et al (1996) Phillips et al (1998) Rahman et al (2003)
(D) (E) (F)
Frequency (%) and type of screening procedure carried out
Baseline Screen
MDCT 100.00
Follow-up MDCT 8.40 Henschke et al. (1999, 2006b)
PET scan 2.20
FNA biopsy 1.30
Annual repeat screen
MDCT 100.00
Follow-up MDCT 2.96 Henschke et al. (2001, 2006b)
PET scan 0.59
FNA biopsy 0.59
Percent of screened patients with lung cancer
Baseline year
Age 40–79 1.3 Henschke et al (2006a)
Age 60–79 2.7 Henschke et al (1999)
Years following baseline year
Age 40–79 0.3 Henschke et al (2006a)
Age 60–79 0.6 Henschke et al (2001)
Screening procedure costs
MDCT $204 $178 $533
Follow-up MDCT $204 $178 $533 Wisnivesky et al (2003) Mahadevia et al (2003) Mahadevia et al (2003)
FNA biopsy $620 $355 $498
PET scan $1,150 $1,150 $3,018 2005 Medicare Rate 2005 Medicare Rate Kelly et al (2004)
(G) (H) (I)
Percent distribution of screened tumours by stage
Stage I 85 64 74
Stage II 4 27 16
Stage IIIA 7 9 8 Henschke et al (1999) Swensen et al (2002) Average
Stage IIIB 4 0 2
Stage IV 0 0 0
(J) (K) (L)
Cost of diagnosis and treatment by stage (diagnosis to death)
Stage I $70033 $79285 $40548
Stage II $47139 $64456 $45249
Stage IIIA $47139 $64456 $41933 Riley et al (1995) Fireman et al (1997) Evans et al (1995)
Stage IIIB $47139 $64456 $36694
Stage IV $31814 $49500 $31265
(M) (N) (O)
Percent 5-year survivors by stage
Stage I 67 88 82 Henschke et al (2006a) Patz et al (2000)
Stage II 55 23 23
Stage IIIA 23 11 11 Mountain et al 1997 Fry et al (1999) Fry et al (1999)
Stage IIIB 5 5 5
Stage IV 1 1 1
(P) (Q) (R)
Abbreviations: FNA¼fine-needle aspiration; MDCT¼multidetector computed tomography; PET¼positron emission tomography. All costs in 2005 USD.
aParenthetical
references are used to identify the combination of variables used for a given scenario. For example, ADGJMF would refer to a scenario in with the input values indicated by
parenthetical reference (A), (D), (G), and so on.
bThe data input listed above apply to both the cohort ages 40–79 years and the cohort aged 60–79 years unless specifically
stated otherwise.
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sare assumed to receive repeat screens with the remaining patients
screened in that year assumed to be new patients receiving a
baseline screen (see Table 3).
Frequency and type of screening procedures carried out. The
procedures carried out as part of the baseline and annual repeat
screens were based on I-ELCAP protocol, revision dated 20
October 2006 (Henschke, 2006). The I-ELCAP recommendations
for the diagnostic workup in participants with a positive result on
the CT include multiple options for nodules meeting certain size
criteria. The protocol used in the I-ELCAP research was reviewed
semi-annually and modified over time and with increasing
experience in the analysis of the study data, which likely impacted
the volume of procedures indicated in years subsequent to the
baseline year because of a temporal, learning effect. In addition, in
the I-ELCAP studies, the decision regarding how to proceed is left
to each participant and the referring physician (Henschke et al,
2006a). As such, the screening procedure protocol utilised in this
analysis (referred to as ‘EDCTS Screening Protocol’) may not
precisely reflect the I-ELCAP protocol or screening procedures
presented in I-ELCAP studies. The EDCTS Screening Protocol
identifies additional workup procedures which, based on the size
of nodules identified in the initial CT scan, would be included in a
patient’s screening costs. We derived the percentage of total
screened patients receiving each additional workup procedure
based on the size distribution of screen tumours reported in the
I-ELCAP baseline and repeat screening studies (Henschke et al,
1999; Henschke et al, 2001) (Tables 4 and 5). A summary of the
percent of screening participants receiving each type of screening
procedure is provided in Table 1. Workup procedures that also
involve treatment of the malignancy, such as video-assisted
thoracoscopic surgical biopsy, are considered as treatment
procedures and are not included as part of screening procedures
in this analysis.
Screen-detected malignant tumours. For the cohort ages 60–79
years, the number of malignant tumours identified by screening in
the baseline and annual repeat screens was derived by multiplying
the percent of malignant tumours identified in the I-ELCAP
studies published in 1999 and 2001 that screened patients aged 60
years and over (Henschke et al, 1999; Henschke et al, 2001) by the
total population screened (Table 1). For the cohort ages 40–79
years, the percentage of malignant tumours identified in the large
collaborative I-ELCAP study published in 2006 that screened
patients aged 40 years and over was used (Henschke et al, 2006a)
(Table 1).
Screening costs. For the EDCTS approach, our model incorpo-
rated three different screening procedure cost estimates for
multidetector CT (MDCT) scans and fine-needle aspiration
biopsies (FNAB), and two cost estimates for positron emission
tomography (PET) scans taken from the clinical literature
(published costs for conventional CT scans were used for MDCT
costs, as there is typically no difference in the cost to the payor).
The first set of estimates for CT and FNAB were based on the
actual costs incurred by I-ELCAP volunteers, as recorded by the
New York-Presbyterian Hospital’s financial system cost database
(Wisnivesky et al, 2003). The second and third sets of estimates
were based on 2003 published figures from a cost effectiveness
study by Mahadevia et al (2003). The Mahadevia et al (2003) study
Table 2 SEER population estimated to receive screening for lung cancer based on inclusion criteria from I-ELCAP reported studies, nationwide smoking
history statistics, and estimated compliance with screening recommendations
a
Year 1 Year 2 Year 3 Year 4 Year 5
SEER population age 40–79 years
b 14277295 14596718 14944483 15262435 15578827
Less: cancer other than non-melanoma skin cancer (see text) 64248 65685 67250 68681 70105
14213047 14531033 14877233 15193754 15508722
Less: estimated patients unfit for surgery (see text) 2089318 2136062 2186953 2233482 2279782
12123729 12394971 12690280 12960272 13228940
Less: o10 pack-year smoking history or nonsmoker (see text)
a 8675948 8870053 9081381 9274592 9466855
3447782 3524918 3608899 3685680 3762085
Less: non-compliance with screening recommendation (see text)
a 1813533 1854107 1898281 1938668 1978857
Total screened population 1634248 1670811 1710618 1747012 1783228
aThe values shown above for 10 pack-year smoking history and compliance with screening recommendations are based on the ‘Input 1’ column in Table 1. For simplicity, values
generated using the columns labelled ‘Input 2’ and ‘Input 3’ values are not shown here.
bFor simplicity, the values associated with the cohort ages 60–79 years are not shown
here.
Table 3 Breakdown of patients receiving a baseline screen vs repeat annual screen in each year analysed
Year 1 Year 2 Year 3 Year 4 Year 5
(A) Total screened population Age 40–79 (see Table 2)
a,b 1634248 1670811 1710618 1747012 1783228
Breakdown of the above total population screened (A) into baseline screens and annual repeat
screens based on assumptions outlined in the section ‘Baseline screening vs annual repeat screening’ (see text):
(B) Dropouts to screening in subsequent years (¼13% (A)) 212452 217205 222380 227112 231820
(C) Patients who will get a repeat screen in the next year (¼(A) (B)) 1421796 1453606 1488238 1519901 1551408
(D) Number of screens that are repeat annual screens (¼(C) from earlier year) NA 1421796 1453606 1488238 1519901
(E) Number of screens that represent new patients receiving baseline screens (¼(A) (D)) (All) 249015 257012 258775 263327
Summary of the breakout of baseline vs annual repeat screens per year:
Patients receiving baseline screen (all in year 1;¼(E) in subsequent years): 1634248 249015 257012 258775 263327
Patients receiving annual repeat screen (none in year 1;¼(D) in subsequent years): 0 1421796 1453606 1488238 1519901
Total Screened Population (sum of baseline and annual repeat screens): 1634248 1670811 1710618 1747012 1783228
aThe values shown above for total screened population are based on the ‘Input 1’ column in Table 1. For simplicity, values generated using the columns labelled ‘Input 2’ and
‘Input 3’ values are not shown here. Refer to Table 1 and Table 2.
bFor simplicity, the values associated with the cohort ages 60–79 years are not shown here.
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sreported base-case costs for lung cancer screening procedures as
well as favourable and unfavourable extremes. Values from both
the favourable and unfavourable scenarios were utilised in
our model (Table 1). The first estimate of PET scan costs
was taken from 2005 Medicare Reimbursement rates, and the
second cost estimate (unfavourable screening estimate) was
taken from a 2004 published cost-effectiveness study by Kelly
et al (2004) (Table 1). We did not consider the potential costs or
implications of using PET-CT, as this was not included in the
EDCTS Screening Protocol (see above). All costs were calibrated to
2005 US dollars using the medical component of the consumer
price index. Screening costs for the STID method were assumed to
be zero.
Quantity and distribution of tumours by stage. Tumour quantity
and distribution by stage for the STID method was based on
SEER data from 1999 to 2003, using lung and bronchus NSCLC
that were invasive, microscopically confirmed, and the patient’s
first primary cancer. SEER tumours of unknown stage were
allocated to stages based on the distribution percentages of the
staged SEER tumours.
The quantity of tumours for the EDCTS method was comprised
of two components: (1) screen-detected malignant tumours
(quantification described above); and (2) non-screen-detected
tumours (‘symptomatic tumours’). For the first year of screening
implementation it was assumed that the number of symptomatic
tumours would include all SEER reported tumours for that year.
For subsequent years, symptomatic tumours were calculated by
multiplying the percent of the population that did not comply with
screening recommendations (based on estimates described for
‘Population Screened’ above) to the SEER tumour population. For
example, if the SEER data identified 1000 tumours in a given year,
and an estimated 60% of the population did not comply with
screening recommendations, then it was assumed that 600
(¼1000 60%) symptomatic tumours would be recorded in that
year in addition to screen-detected tumours. Components (1) and
(2) were added together to determine the total EDCTS tumours
identified each year.
The stage of EDCTS tumours was determined as follows:
(1) Symptomatic tumours, as described above, maintain the SEER
stage distribution, with the same treatment for tumours of
unknown stage as described above for the STID method. (2) Three
estimations were used to determine the number of remaining
screen-detected malignant tumours allocated to each stage.
The first estimation was based on I-ELCAP data (Henschke et al,
1999), the second was based on a prospective cohort CT screening
study by Swensen et al (2002), and the final estimation was an
average of the I-ELCAP and Swensen stage distribution percen-
tages (Table 1).
Cost of treatment by stage. For this parameter, we included
separate estimates and calculations from different sources of
published data on the cost of diagnosis and treatment for lung
cancer by stage. These sources included data based on Medicare
payments for lung cancer patients in nine SEER registries (Riley
et al, 1995), cost of medical care for patients of a Northern
Table 4 Percentage of patients receiving each screening procedure in the baseline screen
I-ELCAP baseline screening results
a Patients % of total
EDCTS screening procedures that would be applied to the nodules
sizes identified by I-ELCAP
(A) Patients receiving initial CT scan: 1000 100 (A) Receive MDCT
Positive non-calcified nodules identified:
(B) Nodules o¼5mm 136 13.6 (B) MDCT in 1 year
b
(C) Nodules 6–10mm, negative upon workup 56 5.6 (C) MDCT in 3 months, assume no growth and therefore additional MDCT in 1 year
b
(D) Nodules 6–10mm, positive upon workup 14 1.4 (D) MDCT in 3 months, assume growth and therefore begin treatment
b
(E) Nodules 11–20mm, negative upon workup 14 1.4 (E) Receive PET, assume negative and therefore additional MDCT in 3 months
(F) Nodules 11–20mm, positive upon workup 8 0.8 (F) Receive PET, assume positive and therefore perform FNAB
(G) Nodules 420mm 5 0.5 (G) All receive FNAB
Abbreviations: EDCTS¼early detection approach using computed tomography screening; FNAB¼fine-needle aspiration biopsy; MDCT¼multidetector computed
tomography; PET¼positron emission tomography.
aReference Henschke et al (1999).
bFor purposes of this screening protocol, FNAB and PET are not utilised for nodules
p10mm in size.
Table 5 Percentage of patients receiving each screening procedure in the annual repeat screen
I-ELCAP annual repeat screening results
a Patients % of total
EDCTS screening procedures that would be
applied to the nodules sizes identified by I-ELCAP
(A) Patients receiving initial CT scan: 1184 100 (A) Receive MDCT
Positive non-calcified nodules identified:
(B) Nodules p5mm, negative upon workup 7 0.6 (B) MDCT in 3 months, assume no growth
b
(C) Nodules p¼5mm, positive upon workup or
not ruled out
9 0.8 (C) MDCT in 3 months, assume growth and therefore patient
receives treatment (no further screening procedures)
b
(D) Nodules 6–10mm, negative upon workup 7 0.6 (C) MDCT in 3 months, assume no growth and therefore additional
MDCT in 1 year
b
(D) Nodules 6–10mm, positive upon workup or
not ruled out
9 0.8 (D) MDCT in three months, assume growth and therefore begin
treatment
b
(E) Nodules 11–20mm, negative upon workup 3 0.3 (F) Receive PET, assume negative and therefore additional MDCT in
3 months
(F) Nodules 11–20mm, positive upon workup or
not ruled out
4 0.3 (E) Receive PET, assume positive and therefore perform FNAB
(G) Nodules 420mm 3 0.3 (G) All receive FNAB
Abbreviations: EDCTS¼early detection approach using computed tomography screening; FNAB¼fine-needle aspiration biopsy; MDCT¼multidetector computed
tomography; PET¼positron emission tomography.
aReference Henschke et al (2001).
bFor purposes of this screening protocol, FNAB and PET are not utilised for nodules
p10mm in size.
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sCalifornia health maintenance organisation (Fireman et al, 1997),
and costs under Canada’s universal health-care system (Evans
et al, 1995). A previous study by Wisnivesky et al (2003) noted that
the overall distribution of the costs of lung cancer treatments by
stage were similar in the United States and Canada. These
estimates included the total lung cancer cost by stage from
diagnosis to death, adjusted to 2005 US dollars (Table 1).
Total screening, diagnosis, and treatment costs. For the EDCTS
approach, total costs were comprised of screening cost and the cost
of treatment by stage. However, calculations for the cost of
treatment by stage included diagnosis and staging procedures that
are also covered in the screening protocol. To avoid double-
counting these expenditures, the screening costs for patients
diagnosed with malignant lung cancer were removed from the total
costs, as these costs are already included in the cost of treatment
by stage. As such, the resulting total costs for the EDCTS approach
includes the sum total of screening costs for patients not diagnosed
with malignant cancer (over 97% of total screening costs) and the
cost of treatment by stage (including diagnostic costs) for the
entire tumour population, including screen-detected and non-
screen-detected tumours. Total costs for the STID approach were
limited to the cost of treatment by stage with screening costs
assumed to be zero.
Five-year survivors. Survival rates were applied to the population
of tumours by stage to determine the estimated number of
associated 5-year survivors. The same survival rates were used for
both the STID and EDCTS calculations. Three different sets of
survival rate estimates were included in our analysis. The first set
of estimates was based on published data on over 5300 lung cancer
cases compiled from The University of Texas MD Anderson
Cancer Center and the classification research database from the
Reference Center for Anatomic and Pathologic Classification of
Lung Cancer (survival based on death from cancer or unknown
cause) (Mountain, 1997). For the second set of estimates, stage I
survival was based on I-ELCAP 10-year survival results (lung
cancer-specific survival; 10-year survival data were used as a
conservative estimate of 5-year survival) (Henschke et al, 2006a),
with stage II through stage IV based on 713043 primary lung
malignancies submitted to the National Cancer Data Base (relative
survival) (Fry et al, 1999). The final set of estimates used the same
National Cancer DataBase rates for stage II through stage IV
disease, with the stage IA survival rate from a 2000 study published
by Patz et al (2000), applied to the stage I tumour populations (all-
cause survival) (Table 1).
Ratio of total CP5YS for 729 scenarios
Using the inputs described above, 729 scenarios were generated by
combining all possible combinations of the variables containing
multiple input values in Table 1. For example, the percent of the
population eligible for screening (X10 pack-year history of
smoking) has three possible input values: (A), (B), and (C).
Similarly, the estimated compliance percentage has three possible
input values: (D), (E), and (F). Each combination of these values
was used in a separate scenario examined (AD, AE, AF, BD, and so
on). This method was applied to all six variables that contain
multiple input values (three input values each) for a total of 729
(¼3
6) total scenarios for each cohort analysed (Figure 1). Each
unique combination of input values was given a six letter ‘scenario
code’ based on the combination of input identifiers utilised. For
example, the scenario code of ADGJMP represents a scenario in
which estimate (A) was used for the percent of US adults with a 10
pack-year history of smoking (28.4%), estimate (D) was used for
the compliance with screening recommendations (27%), estimates
(G) were used for screening procedure costs, and so on.
The total costs, total 5-year survivors, and the ratio of total cost to
5-year survivors were analysed for all 1458 scenarios (729 scenarios
for each cohort). The CP5YS ratio was determined by first
calculating the estimated number of NSCLC tumours distributed
by stage for the 5-year period for both the STID and EDCTS
approaches. The cost of diagnosis and treatment by stage were
applied to these tumour populations, with screening cost also added
to the EDCTS costs. The estimated percent of 5-year survivors for
each stage was also applied to the tumour populations. The ratio of
total CP5YS was then calculated (see Figure 2).
RESULTS
Note that the total survivors and total cost figures reported in this
analysis refer only to the subset of the US population studied and
are not extrapolated to represent nationwide estimates.
Figure 1 Illustration of the method of using multiple input value combinations used to generate 729 scenarios for each cohort. Identification codes (A),
(B), and (C) represent the three input values for the percent of US adult smokers from Table 1. Similarly, (D), (E), and (F) represent three input values for
percent complying with screening recommendations, and (G), (H), and (I) represent the three input values for screening procedure costs. ‘Scenario code’
refers to the combination of input value identifiers for multiple variables.
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Across all 729 scenarios analysed for the cohort ages 40–79 years,
the total CP5YS ranged from $157300 to $293800 for the STID
method, and from $105100 to $288100 for the EDCTS method.
The costs per 5-year survivor were higher for the STID approach in
75% of the scenarios analysed, ranging from approximately $5700
to $110000 increased CP5YS under the STID method for those
scenarios (Figure 3) (See the Appendix Table A1 for a listing of the
CP5YS for all 729 scenarios). The total number of 5-year survivors
over the 5-year period analysed was higher for the EDCTS method
for all 729 scenarios, ranging from approximately 13400 to 39300
increased 5-year survivors under the EDCTS method, which is a
112–309% increase. The total screening, diagnosis, and treatment
costs were also higher for the EDCTS method in all 729 scenarios,
ranging from approximately $1.5B to $8.7B in increased total costs,
which is a 77–256% increase (Figure 4).
The EDCTS method resulted in a 27–66% increase in the
number of tumours identified when compared with the STID
method (Table 6).
Scenario code BDHJOQ was associated with the lowest CP5YS of
approximately $105100 per 5-year survivor for the EDCTS method
and $157300 for the STID method. Scenario code CEIKNP was
associated with the highest CP5YS of approximately $288100 per
5-year survivor for the EDCTS method and $293800 for the STID
method.
The scenario most favourable towards the EDCTS method in
terms of the comparative decrease in costs per 5-year survivor was
scenario code BDHJNR, in which the EDCTS CP5YS was
approximately $110000 less than the STID ratio for that same
scenario (305% more EDCTS 5-year survivors in that scenario).
The scenario least favourable towards the EDCTS method in
terms of the comparative increase in costs per 5-year survivor
was scenario code BDIKOR, in which the EDCTS CP5YS was
Screened population
Un-screened population
Figure 2 Schematic illustration of the calculation of costs and 5-year survivors for the early detection computed tomography screening (EDCTS) method.
Costs and 5-year survivors for the symptomatic tumour identification (STID) method follow the path of the ‘un-screened population’ above.
wThe calculation
exemplified by the above schematic was separately carried out for age range 40–79 years and age range 60–79 years.
Scenario code, sorted ascending by the increase in STID costs per 5-year survivor  (= STID CP5YS – EDCTS CP5YS)
Cohort ages 40 – 79 years
Cohort ages 60 – 79 years
Scenario code, sorted ascending by the increase in STID costs per 5-year survivor  (= STID CP5YS – EDCTS CP5YS)
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Figure 3 Increase in STID costs per 5-year survivor (CP5YS) compared with the EDCTS method (STID CP5YS–EDCTS CP5YS). The scenario codes
represent the combination of input variables and associated codes from Table 1. All 729 scenario codes are represented in each graph, though not all Y axis
values are labelled. Note that the data are not sorted alphabetically by the X axis scenario codes. STID¼symptomatic tumour identification; EDCTS¼early
detection approach using computed tomography screening. Note: Across all scenarios, the total number of 5-year survivors was higher for the EDCTS
method, ranging from approximately 13400 to 39300 increased 5-year survivors for the population aged 40–79 years and 9300–27400 for the population
aged 60–79 years.
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sapproximately $53400 more than the STID ratio for that same
scenario (248% more EDCTS 5-year survivors in that scenario).
Cohort ages 60–79 years
Across all 729 scenarios analysed for the cohort ages 60–79 years,
the total CP5YS ranged from $149400 to $282100 for the
STID method, and from $86400 to $233300 for the EDCTS
method. The costs per 5-year survivor were higher for the STID
approach in all scenarios analysed, ranging from approximately
$5800 to $116700 increased CP5YS under the STID method for
those scenarios (Figure 3) (See the Appendix Table A2 for a listing
of the CP5YS for all 729 scenarios). The total number of 5-year
survivors over the 5-year period analysed was higher for the
EDCTS method for all 729 scenarios, ranging from approximately
9000 to 26600 increased 5-year survivors under the EDCTS
method, which is a 98–272% increase. The total screening,
diagnosis, and treatment costs were also higher for the EDCTS
method in all 729 scenarios, ranging from approximately $728M to
$4.0B in increased total costs, which is a 50–159% increase
(Figure 4).
The EDCTS method resulted in a 24–60% increase in the
number of tumours identified when compared with the STID
method (Table 6).
Scenario code BDHJOQ was associated with the lowest CP5YS of
approximately $86400 per 5-year survivor for the EDCTS method and
$149400 for the STID method. Scenario code CEIJNP was associated
with the highest CP5YS of approximately $233300 per 5-year survivor
for the EDCTS method and $282000 for the STID method.
The scenario most favourable towards the EDCTS method in
terms of the comparative decrease in costs per 5-year survivor was
scenario code BDHJNR, in which the EDCTS CP5YS was
approximately $116700 less than the STID ratio for that same
scenario (269% more EDCTS 5-year survivors in that scenario).
The scenario least favourable towards the EDCTS method in terms
of the comparative decrease in costs per 5-year survivor was
scenario code CEIKOQ, in which the EDCTS CP5YS was
approximately $5800 less than the STID ratio for that same
scenario (98% more EDCTS 5-year survivors in that scenario).
DISCUSSION
The advisability of population screening for lung cancer is
currently a topic of active debate. Because of the potential high
cost of lung cancer screening programmes, cost-effectiveness
questions are an important component to be evaluated. This article
attempts to inform the debate by a multivariable analysis model.
We incorporated a range of optimistic and pessimistic input
variables taken from literature sources on both sides of this debate.
In addition, this analysis presents an important method for
evaluating a lung cancer-screening programme in contrast to
Cohort ages 60 – 79 years
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Figure 4 Comparison of the total screening, diagnosis, and treatment costs between the STID and EDCTS methods. The scenario codes represent the
combination of input variables and associated codes from Table 1. All 729 scenario codes are represented in each graph, though not all Y axis values are
labelled. Note that the data are not sorted alphabetically by the X axis scenario codes. STID¼symptomatic tumour identification, EDCTS¼early detection
approach using computed tomography screening.
Symptomatic tumour identification vs proactive CT
AW Castleberry et al
889
British Journal of Cancer (2009) 101(6), 882–896 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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efficacy of treatment regimens, particularly when there is little
chance of long-term survival, as in the treatment of stage IIIB and
IV NSCLC with chemotherapy. Owing to the frequent use of the
QALY metric in the literature, we have provided for the reader a
cost-per-year of life calculation for all 729 scenarios in the
Appendix Table A3 and Table A4 to allow a rough comparison to
other studies evaluating cost-effectiveness on a per-year basis. It
should be emphasised, however, that the data in Table A3 and
Table A4 is calculated assuming that these lung cancer survivors
live only 5 years. It is therefore a conservative estimate and
overstates the cost-per-year of life, as many lung cancer survivors
detected by screening will live longer than 5 years (Marcus et al,
2000; Sobue et al, 2002; Henschke et al, 2006a).
The combination of decreased CP5YS and increased 5-year
survivors in all 729 scenarios for the cohort ages 60–79 years and
in the majority of scenarios for the cohort ages 40–79 years suggests
that health-care dollars spent on proactively screening for lung
cancer may achieve higher cost-effectiveness. These data may also
suggest advantages in focusing a screening programme on patients
aged 60 years or older as the marginal costs for implementing
screening in the cohort ages 60–79 years were between 46 and 60%
of the marginal cost for the cohort ages 40–79 years, with greater
cost effectiveness in the 60–79 age group when compared with the
STID method (see Figure 3). These findings are consistent with a
2008 study by Whynes (2008), analysing the potential cost
effectiveness of lung cancer screening in the United Kingdom.
The I-ELCAP study results have shown the ability of CT
scanning to detect asymptomatic lung cancers. By definition, a
lung cancer programme that detects symptomatic and asympto-
matic malignancies will diagnose more tumours at the onset of the
programme than a system that detects symptomatic tumours
alone, as illustrated in Figure 5. The magnitude of this increase is
unknown, and sufficient information to evaluate the reason-
ableness of the 24–66% increase in diagnosed tumours under the
EDCTS method presented in this model is currently unavailable.
Additional long-term data on the prevalence of lung cancer in an
asymptomatic at-risk population annually screened over multiple
years are needed to enable further estimates in this area.
Increased total costs associated with a successful proactive screen-
ing programme are to be expected, not only due to the cost of
screening procedures, but also more importantly due to the increased
patient survival and related increase in long-term treatment costs and
follow-up care. The available data for cost of treatment utilised in this
study (see Table 1, inputs M, N, and O) all indicate that the treatment
for early stage cancer is more expensive than cancers detected in
stages IIIB and IV. This is counter-intuitive, as stage I NSCLC is
treated by surgery alone, whereas advanced stage lung cancers require
multimodality treatment, adding the cost of expensive radiation and
chemotherapy. Furthermore, treatment of advanced stage lung cancer
is changing, which may potentially shift this balance, making the
treatment of late-stage cancers increasingly more expensive. The
percentage of patients in higher stages who are receiving expensive
radiation therapy and chemotherapy appears to be increasing
(Ramsey et al, 2004; Langer et al,2 0 0 5 ) .I na d d i t i o n ,n e wm o l e c u l a r
‘targeted’ medications used in second- and third-line treatment may
markedly increase treatment costs (Adis International Ltd. Erlotinib,
2003). As I-ELCAP data report increased actuarial 10-year survival of
80% with screen-detected tumours (Henschke et al, 2006a), which is
dramatically different than the survival of symptom-detected tumours
which are disproportionately detected in later stages, it would follow
that increased costs of long-term care would be expected. The cost of
follow-up and care in the majority of survivors, however, adds little to
routine health-care expenditures, and only a small minority would
require downstream salvage or palliative radiation therapy and
chemotherapy. In addition, the cost of screening programmes and
treatment may reasonably be expected to decrease as a result of
economies of scale, if lung cancer screening were implemented at a
state or nationwide level.
It is important to consider several potential sources of bias when
evaluating lung cancer screening:
(1) ‘Overdiagnosis bias’: small, slow-growing lesions are detected by
screening for intervention that would never become symptomatic
within a patient’s lifetime in the absence of screening (Black et al,
2006). This could be caused by an improper pathological diagnosis;
however, all lung cancers in the I-ELCAP study are vetted by a panel of
prominent international pathologists (Flieder et al, 2006). With regard
to the theoretical possibility of screening the detection of very slow
growing malignant neoplasms that do not cause symptoms during the
patient’s anticipated normal lifespan, for ethical reasons, a randomised
trial comparing surgery with no surgery for stage I NSCLC is not
possible. However, data on untreated screen-detected NSCLC from
screening studies including the Johns Hopkins study, the Memorial
Sloan-Kettering study, the Mayo Clinic study, and the I-ELCAP study
indicate that almost all of these untreated patients die within 5 years
(Flehinger et al,1 9 9 2 ;H e n s c h k eet al,2 0 0 6 a ) .As t u d yb yR a zet al
(2007), examined the natural history of patients with stage I NSCLC
and concluded that long-term survival with untreated stage I NSCLC is
uncommon with an overall survival of 6% for untreated stage I
Table 6 Comparison of the total number of diagnosed tumours between the STID and EDCTS methods
Cohort ages 40–79 years
a
Scenario code (includes all scenario codes
Total number of diagnosed tumours (5-year period)
Increase in % Increase in
beginning with the first two letters indicated)
b STID EDCTS
c EDCTS tumours EDCTS tumours
ADy 86818 31357 57
AEy 73323 17862 32
AFy 82849 27388 49
BDy 55461 92044 36583 66
BEy (Same for all scenarios) 76300 20839 38
BFy 87414 31953 58
CDy 81592 26131 47
CEy 70346 14885 27
CFy 78284 22823 41
Abbreviations: EDCTS¼early detection approach using computed tomography screening; STID¼symptomatic tumour identification.
aApplying the same analysis to the cohort
ages 60–79 years (not shown here), the increase in tumours identified under the EDCTS method ranged from 24 to 60%.
bThe scenario codes represent the combination of
input variables and associated codes from Table 1.
cThe estimated number of EDCTS tumour varies depending on the following input parameters: (1) Estimated percentage of
patients with a 10 pack-year history of smoking; and (2) the estimated percent of patients complying with screening recommendations. As such, the EDCTS number of diagnosed
tumours will vary for scenario codes representing different values for these input parameters
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from 885 cases of stage IA lung cancer and concluded that almost all
diagnosed cases of Stage IA lung cancer have a malignant natural
course, fatal if not treated, thus representing genuine cancer. Although
some speculate that the explanation for the paradoxical result in the
Mayo Lung Trial of increased survival but no reduction in mortality
with chest radiograph screening was due to, in part, overdiagnosis bias
(Patz, 2006), no empirical evidence to support this theory exists.
Furthermore, Yankelevitz et al, (2003) analysed the doubling time of
stage I tumours in the Mayo Lung Trial and concluded that ‘the
hypothesis that early-stage lung tumours diagnosed on chest radio-
graphy during lung carcinoma screening may frequently be over-
diagnosed, indolent cases needs to be rejected’.
Another form of overdiagnosis could exist in instances where
comorbid disease would kill the patient before symptoms of lung
cancer were experienced. This form of overdiagnosis bias can be
reasonably assumed to be rendered largely irrelevant in medical
environments, where patients are managed with good, sensible
clinical judgment by physicians adept in identifying comorbid
disease and reasonably accurately estimating the anticipated
survival of their patients. Furthermore, in this study we have
carefully taken into account the percentage of patients eligible for
screening who have serious comorbid disease and excluded them
from our analysis (refer to the ‘Population Screened’ section of the
Materials and Methods above). We have been conservative in this
approach by additionally excluding patients aged 80 years and
above from screening, although many 80-year-olds are perfectly
capable of undergoing minimally invasive surgical resection of
lung cancers or being treated with radiationtherapy.
Finally, overdiagnosis could result if spontaneous remission of a
preclinical cancer were to occur. Case reports of this phenomenon
are extremely rare (Kappauf et al, 1997).
(2) ‘Length bias’: detection of more patients with less aggressive
disease and fewer of those with more aggressive disease, because
the duration of asymptomatic disease is longer in less aggressive
tumours (Black et al, 2006). This also could result in ‘over-
diagnosis’, discussed above. The baseline round of screening is
inherently different from the repeat rounds because cancers with a
longer latent (asymptomatic) phase are more frequently identified
in the baseline round, whereas cancers found in repeat rounds are
found earlier in their latent phase than in the baseline round
(Morrison, 1982; Henschke and Yankelevitz, 2008). Cancers that
are diagnosed at baseline, thus, tend to grow more slowly than
does the subtype in general; they also grow more slowly than do
tumours that are diagnosed in repeated screenings. As noted by
the I-ELCAP researchers, this fact does not introduce a bias, but it
may call for making a distinction between baseline screening and
repeated screening (Henschke et al, 2007). ‘Length bias’ also
implies that the faster growing tumours may present symptoma-
tically between screening exams, however, the I-ELCAP data
showed a very low incidence of such cases.
(3) ‘Lead-time bias’: screening-detected patients are accorded
extended survival times solely because cancer was detected earlier
owing to screening, although death occurred at the same time as
would have happened without screening (Black et al, 2006). To
address this potential source of bias, the estimated percentage of
stage I 5-year survivors for all scenarios using input variable ‘Q’
(see Table 1) are based on 10-year survival percentages reported by
I-ELCAP (Henschke et al, 2006a). If lead-time bias was evident in
this study, a large number of individuals who survived 5 years
would be expected to die before 10 years; the I-ELCAP survival
curve shows no decrement in survival between 5 and 10 years
(Henschke et al, 2006a).
Although some emphasise that the risks and complications of
lung cancer screening may be considerable (Bach et al, 2007), the
minutes of National Cancer Institute’s National Lung Screen Trial
(NLST) Data Safety Monitoring Board (DSMB), which we have
reviewed, indicate that during the first 5 years of the study, which
began in 2002, no unanticipated complications or risks have been
recognised. The DSMB, which is responsible for the safety of NLST
Time
Legend describing background shading
Figure 5 Illustration demonstrating the theory for an increase in the number of tumours identified by screeingfor asymptomatic malignancies in addition to
identifying symptomatic tumours. ‘Tumour crop’ refers to a cohort of lung cancers that clinically manifested at a point in time (i.e., a group of tumours for
which the tumours’ inception is at the same time point represented on the X axis).
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sresearch subjects, has neither terminated the study nor reported
information on new complications to study subjects.
Limitations
Input variables based on SEER data may not be representative of actual
nationwide lung cancer incidence or staging. Our model does not
account for costs associated with complications from biopsies or other
screening procedures, nor does it account for the increase in capital
equipment and resources necessary to implement large-scale compre-
hensive CT screening programmes. In addition, our study design does
not consider the indirect cost of lost productivity attributable to lung
cancer morbidity and mortality. Of the estimated $167 billion costs of
all diseases caused by tobacco products, indirect costs ($92 billion) are
substantially higher than direct costs (Centers for Disease Control and
Prevention, 2005). As survival increases, indirect costs attributable to
loss of patient income, spousal income, and other factors may
reasonably be expected to diminish substantially. This study is based
on a representative subset of the US population and it is beyond the
scope of this analysis to extrapolate the results to a state or nationwide
level. The model does not factor in any additional benefit conferred by
survival beyond 5 years. On the basis of the results from the Mayo
Lung Trial (Marcus et al, 2000), Japanese Anti-Lung Cancer
Association (ALCA) trial (Sobue et al, 2002), and I-ELCAP (Henschke
et al, 2006a), there is a strong evidence to suggest that the majority of
5-year survivors will continue to survive for 10, 15, and even 20 years
following diagnosis and treatment. Finally, there is no accurate method
to calculate a dollar value for not dying of lung cancer in an individual
or group of individuals with lung cancer.
CONCLUSION
Our analytical model offers an innovative tool that provides data
estimates that contribute insights into the continuing debate on
the wisdom and advisability of implementing state and/or nation-
wide CT screening programmes. The predicted increase in long-
term survival with CT screening and the potential for better
utilisation of health-care dollars in terms of CP5YS, particularly
when screening patients over the age of 60 years, are critically
important considerations in directing effective future lung cancer
management strategy.
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Appendix
See Tables A1 to A4
Table A1 Summary of the cost per 5-year survivor for all 729 scenarios
a analysed for the cohort ages 40–79 years (2005 USD, in thousands)
EDCTS
ABC
DEFDEFDEF
S T I D GH I GH I GH I GH I GH I GH I GH I GH I GH I
P 219 180 173 259 187 181 251 181 175 257 179 172 259 186 180 252 180 174 258 180 174 258 188 183 250 182 176 256
M Q 199 146 141 210 155 151 208 148 143 210 145 140 211 154 149 209 147 142 210 147 142 210 156 152 208 149 144 210
R 211 156 151 225 165 161 223 158 153 224 155 150 225 164 159 223 157 152 225 157 152 225 167 162 222 159 154 224
P 294 207 201 286 223 218 288 211 205 287 206 199 286 221 216 288 209 203 287 209 203 286 226 221 288 213 207 287
J N Q 267 169 164 233 185 181 239 172 167 234 167 162 232 183 178 238 171 166 234 170 165 234 188 184 240 174 169 235
R 283 180 175 249 198 193 255 184 179 250 179 173 249 195 191 254 183 177 250 182 177 250 201 196 256 186 181 251
P 173 136 130 215 143 138 208 138 132 214 136 129 216 142 137 209 137 131 215 137 131 215 144 139 206 139 133 213
O Q 157 111 106 175 119 114 172 113 108 175 110 105 176 118 113 173 112 107 175 112 107 175 120 116 172 114 109 174
R 167 119 113 187 127 122 184 121 115 187 118 112 188 126 121 185 120 114 187 120 114 187 128 124 183 122 116 186
P 219 176 169 256 184 179 249 178 171 254 175 169 257 183 177 250 177 170 255 177 170 255 185 180 248 179 173 254
M Q 199 164 158 239 171 166 232 166 160 238 164 158 240 170 165 233 165 159 238 165 159 239 172 167 230 167 161 237
R 211 175 168 255 182 177 246 176 170 253 174 168 255 181 175 248 176 169 254 176 169 254 183 178 245 177 171 252
P 294 206 200 287 223 217 288 210 204 287 205 198 287 220 215 288 208 202 287 208 202 287 225 220 288 212 206 287
K N Q 267 193 187 268 207 202 268 196 190 268 192 186 268 205 200 268 195 189 268 195 189 268 209 204 268 198 192 268
R 283 205 199 285 220 215 285 209 202 285 204 197 285 218 213 285 207 201 285 207 201 285 222 217 285 210 204 285
P 173 140 134 221 146 141 212 142 135 219 140 133 221 146 140 213 141 135 219 141 135 220 147 142 210 142 136 217
O Q 157 131 125 206 136 131 197 132 127 204 131 125 207 135 130 198 132 126 205 132 126 205 137 132 195 133 127 203
R 167 140 133 219 145 140 209 141 135 217 139 133 220 144 139 211 140 134 218 140 134 218 146 141 208 141 135 216
P 219 178 171 257 185 180 250 179 173 256 177 170 258 184 179 251 179 172 257 179 172 257 186 181 249 180 174 255
M Q 199 155 149 224 163 158 220 157 151 223 154 149 225 162 157 221 156 150 224 156 150 224 164 160 219 158 152 223
R 211 165 159 239 173 169 234 167 161 238 165 159 240 172 167 235 166 160 239 166 160 239 175 170 234 168 163 238
P 294 207 201 287 223 218 288 211 204 287 205 199 286 221 215 288 209 203 287 209 202 287 225 220 288 213 207 287
L N Q 267 181 175 250 196 191 253 184 179 251 179 173 250 194 189 253 182 177 250 182 177 250 198 194 253 186 181 251
R 283 193 187 267 209 204 270 196 190 267 191 185 266 207 201 269 195 189 267 194 188 267 211 207 270 198 193 268
P 173 139 132 218 145 140 210 140 134 216 138 131 219 144 139 211 139 133 217 139 133 217 146 141 209 141 135 215
O Q 157 121 115 190 127 123 184 122 117 189 120 115 191 126 122 185 122 116 190 122 116 190 128 124 183 123 118 188
R 167 129 123 203 136 131 197 130 125 202 128 122 204 135 130 197 130 124 202 130 124 202 137 132 195 131 126 201
Early detection approach using computed tomography screening (EDCTS).
Symptomatic tumour identification (STID) method.
aRow and column headings represent input variable identification codes corresponding to Table 1. Each figure within the table above represents a unique combination of input
variables with the six-letter combination of row and column headings corresponding to the ‘scenario code’ for that set of variables (see Figure 1 for further explanation of
scenario codes). Note that the STID costs per 5-year survivor do not change across variables A through I.
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sTable A2 Summary of the cost per 5-year survivor for all 729 scenarios
a analysed for the cohort ages 60–79 years (2005 USD, in thousands)
EDCTS
ABC
DEFDEFDEF
STID G H I G H I G H I G H I G H I G H I G H I G H I G H I
P 211 154 151 191 165 162 195 156 153 192 152 149 191 163 161 195 155 152 192 155 152 192 167 164 196 158 155 193
M Q 191 125 123 156 137 135 162 128 125 157 124 121 155 135 133 161 126 124 156 126 124 156 139 137 163 129 127 158
R 202 134 131 167 146 144 173 137 134 168 133 130 166 144 142 172 135 133 167 135 132 167 148 146 174 138 136 169
P 282 181 178 219 201 199 231 186 183 222 180 177 218 198 196 230 184 181 221 184 181 220 204 202 233 188 186 223
J N Q 254 148 145 178 167 165 192 152 150 181 146 143 177 164 162 190 150 148 180 150 147 180 170 168 194 154 152 183
R 270 158 155 191 178 176 205 163 160 194 156 153 189 176 173 203 160 158 193 160 158 192 182 180 207 165 163 196
P 166 110 107 148 121 119 151 113 110 149 109 106 148 120 117 151 112 109 148 112 109 148 123 121 152 114 111 149
O Q 149 90 87 121 101 99 126 92 90 122 89 86 120 99 97 125 91 89 121 91 89 121 102 100 127 94 91 122
R 159 96 94 129 107 105 134 99 96 130 95 92 128 106 104 134 98 95 130 97 95 130 109 107 135 100 98 131
P 211 150 146 188 162 159 192 152 149 189 148 145 187 160 158 192 151 148 188 151 148 188 164 161 193 154 151 189
M Q 191 140 137 175 150 148 178 142 139 176 139 136 175 148 146 178 141 138 176 141 138 175 151 149 179 143 141 176
R 202 148 145 186 159 157 190 151 148 187 147 144 186 158 155 189 150 147 187 150 147 187 161 159 190 152 149 187
P 282 180 177 218 200 198 231 185 182 221 178 175 217 198 195 229 183 180 220 182 179 220 203 201 233 187 184 223
K N Q 254 168 165 204 186 183 214 172 169 206 166 163 203 183 181 213 170 167 205 170 167 205 188 186 216 174 172 207
R 270 179 176 217 197 195 228 183 180 219 177 174 216 195 192 226 181 178 218 181 178 218 200 198 229 185 183 221
P 166 114 111 152 124 122 155 116 113 153 113 110 152 123 120 154 115 112 152 115 112 152 126 123 155 117 115 153
O Q 149 106 103 142 115 113 143 108 105 142 105 102 142 114 111 143 107 104 142 107 104 142 116 114 144 109 107 142
R 159 113 110 151 122 120 152 115 112 151 112 109 151 121 118 152 114 111 151 114 111 151 124 121 153 116 113 151
P 211 152 148 189 163 161 194 154 151 190 150 147 189 162 159 193 153 150 190 153 150 190 165 163 194 156 153 191
M Q 191 132 129 165 143 141 170 135 132 166 131 128 165 142 140 169 133 131 166 133 131 166 145 143 171 136 134 167
R 202 141 138 176 153 150 181 144 141 177 140 137 176 151 149 181 142 140 177 142 139 177 155 152 182 145 142 178
P 282 181 178 219 201 198 231 185 182 222 179 176 218 198 196 230 183 180 220 183 180 220 204 202 233 188 185 223
L N Q 254 158 155 191 176 174 203 162 159 194 156 153 190 174 171 201 160 157 192 160 157 192 179 177 205 164 162 195
R 270 168 165 203 188 186 216 173 170 206 166 163 202 185 183 215 171 168 205 170 168 205 191 189 218 175 172 208
P 166 112 109 150 123 120 153 115 112 151 111 108 150 121 119 153 113 110 151 113 110 150 124 122 154 116 113 151
O Q 149 98 95 131 108 106 134 100 98 132 97 94 131 106 104 134 99 96 131 99 96 131 109 107 135 101 99 132
R 159 104 101 140 115 112 143 107 104 140 103 100 139 113 111 143 106 103 140 105 103 140 116 114 144 108 105 141
Early detection approach using computed tomography screening (EDCTS).
Symptomatic tumour identification (STID) method.
aRow and column headings represent input variable identification codes corresponding to Table 1. Each figure within the table above represents a unique combination of input
variables with the six-letter combination of row and column headings corresponding to the ‘scenario code’ for that set of variables (see Figure 1 for further explanation of
scenario codes). Note that the STID costs per five-year survivor do not change across variables A through I.
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sTable A3 Summary of the cost per lung cancer survivor year of life for all 729 scenarios
a analysed for the cohort ages 40–79 years (2005 USD, in
thousands)
b
EDCTS
ABC
DEFDEFDEF
STID G H I G H I G H I G H I G H I G H I G H I G H I G H I
P 4 4 3 63 55 23 73 65 03 63 55 13 63 45 23 73 65 03 63 55 23 63 55 23 83 75 03 63 55 1
M Q 40 29 28 42 31 30 42 30 29 42 29 28 42 31 30 42 29 28 42 29 28 42 31 30 42 30 29 42
R 4 2 3 13 04 53 33 24 53 23 14 53 13 04 53 33 24 53 13 04 53 13 04 53 33 24 43 23 14 5
P 5 9 4 14 05 74 54 45 84 24 15 74 14 05 74 44 35 84 24 15 74 24 15 74 54 45 84 34 15 7
J NQ 5 3 3 43 34 73 73 64 83 43 34 73 33 24 63 73 64 83 43 34 73 43 34 73 83 74 83 53 44 7
R 5 7 3 63 55 04 03 95 13 73 65 03 63 55 03 93 85 13 73 55 03 63 55 04 03 95 13 73 65 0
P 3 5 2 72 64 32 92 84 22 82 64 32 72 64 32 82 74 22 72 64 32 72 64 32 92 84 12 82 74 3
O Q 31 22 21 35 24 23 34 23 22 35 22 21 35 24 23 35 22 21 35 22 21 35 24 23 34 23 22 35
R 3 3 2 42 33 72 52 43 72 42 33 72 42 23 82 52 43 72 42 33 72 42 33 72 62 53 72 42 33 7
P 4 4 3 53 45 13 73 65 03 63 45 13 53 45 13 73 55 03 53 45 13 53 45 13 73 65 03 63 55 1
M Q 40 33 32 48 34 33 46 33 32 48 33 32 48 34 33 47 33 32 48 33 32 48 34 33 46 33 32 47
R 4 2 3 53 45 13 63 54 93 53 45 13 53 45 13 63 55 03 53 45 13 53 45 13 73 64 93 53 45 0
P 5 9 4 14 05 74 54 35 84 24 15 74 14 05 74 44 35 84 24 05 74 24 05 74 54 45 84 24 15 7
KNQ 5 3 3 93 75 44 14 05 43 93 85 43 83 75 44 14 05 43 93 85 43 93 85 44 24 15 44 03 85 4
R 5 7 4 14 05 74 44 35 74 24 05 74 13 95 74 44 35 74 14 05 74 14 05 74 44 35 74 24 15 7
P 3 5 2 82 74 42 92 84 22 82 74 42 82 74 42 92 84 32 82 74 42 82 74 42 92 84 22 82 74 3
O Q 31 26 25 41 27 26 39 26 25 41 26 25 41 27 26 40 26 25 41 26 25 41 27 26 39 27 25 41
R 3 3 2 82 74 42 92 84 22 82 74 32 82 74 42 92 84 22 82 74 42 82 74 42 92 84 22 82 74 3
P 4 4 3 63 45 13 73 65 03 63 55 13 53 45 23 73 65 03 63 45 13 63 45 13 73 65 03 63 55 1
M Q 40 31 30 45 33 32 44 31 30 45 31 30 45 32 31 44 31 30 45 31 30 45 33 32 44 32 30 45
R 4 2 3 33 24 83 53 44 73 33 24 83 33 24 83 43 34 73 33 24 83 33 24 83 53 44 73 43 34 8
P 5 9 4 14 05 74 54 45 84 24 15 74 14 05 74 44 35 84 24 15 74 24 05 74 54 45 84 34 15 7
LNQ 5 3 3 63 55 03 93 85 13 73 65 03 63 55 03 93 85 13 63 55 03 63 55 04 03 95 13 73 65 0
R 5 7 3 93 75 34 24 15 43 93 85 33 83 75 34 14 05 43 93 85 33 93 85 34 24 15 44 03 95 4
P 3 5 2 82 64 42 92 84 22 82 74 32 82 64 42 92 84 22 82 74 32 82 74 32 92 84 22 82 74 3
O Q 31 24 23 38 25 25 37 24 23 38 24 23 38 25 24 37 24 23 38 24 23 38 26 25 37 25 24 38
R 3 3 2 62 54 12 72 63 92 62 54 02 62 44 12 72 63 92 62 54 02 62 54 02 72 63 92 62 54 0
Early detection approach using computed tomography screening (EDCTS).
Symptomatic tumour identification (STID) method.
aRow and column headings represent input variable identification codes corresponding to Table 1. Each figure within the table above represents a unique combination of input
variables with the six-letter combination of row and column headings corresponding to the ‘scenario code’ for that set of variables (see Figure 1 for further explanation of
scenario codes). Note that the STID costs per 5-year survivor do not change across variables A through I.
bAs a conservative estimate, this calculation assumes that the lung
cancer survivors live no longer than 5 years.
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sTable A4 Summary of the cost per lung cancer survivor year of life for all 729 scenarios
a analysed for the cohort ages 60–79 years (2005 USD, in
thousands)
b
EDCTS
ABC
DEFDEFDEF
STID G H I G H I G H I G H I G H I G H I G H I G H I G H I
P 4 2 3 13 03 83 33 23 93 13 13 83 03 03 83 33 23 93 13 03 83 13 03 83 33 33 93 23 13 9
M Q 38 25 25 31 27 27 32 26 25 31 25 24 31 27 27 32 25 25 31 25 25 31 28 27 33 26 25 32
R 4 0 2 72 63 32 92 93 52 72 73 42 72 63 32 92 83 42 72 73 32 72 63 33 02 93 52 82 73 4
P 5 6 3 63 64 44 04 04 63 73 74 43 63 54 44 03 94 63 73 64 43 73 64 44 14 04 73 83 74 5
J NQ 5 1 3 02 93 63 33 33 83 03 03 62 92 93 53 33 23 83 03 03 63 02 93 63 43 43 93 13 03 7
R 5 4 3 23 13 83 63 54 13 33 23 93 13 13 83 53 54 13 23 23 93 23 23 83 63 64 13 33 33 9
P 3 3 2 22 13 02 42 43 02 32 23 02 22 13 02 42 33 02 22 23 02 22 23 02 52 43 02 32 23 0
O Q 30 18 17 24 20 20 25 18 18 24 18 17 24 20 19 25 18 18 24 18 18 24 20 20 25 19 18 24
R 3 2 1 91 92 62 12 12 72 01 92 61 91 82 62 12 12 72 01 92 61 91 92 62 22 12 72 02 02 6
P 4 2 3 02 93 83 23 23 83 03 03 83 02 93 73 23 23 83 03 03 83 03 03 83 33 23 93 13 03 8
M Q 38 28 27 35 30 30 36 28 28 35 28 27 35 30 29 36 28 28 35 28 28 35 30 30 36 29 28 35
R 4 0 3 02 93 73 23 13 83 03 03 72 92 93 73 23 13 83 02 93 73 02 93 73 23 23 83 03 03 7
P 5 6 3 63 54 44 04 04 63 73 64 43 63 54 34 03 94 63 73 64 43 63 64 44 14 04 73 73 74 5
KNQ 5 1 3 43 34 13 73 74 33 43 44 13 33 34 13 73 64 33 43 34 13 43 34 13 83 74 33 53 44 1
R 5 4 3 63 54 33 93 94 63 73 64 43 53 54 33 93 84 53 63 64 43 63 64 44 04 04 63 73 74 4
P 3 3 2 32 23 02 52 43 12 32 33 12 32 23 02 52 43 12 32 23 02 32 23 02 52 53 12 32 33 1
O Q 30 21 21 28 23 23 29 22 21 28 21 20 28 23 22 29 21 21 28 21 21 28 23 23 29 22 21 28
R 3 2 2 32 23 02 42 43 02 32 23 02 22 23 02 42 43 02 32 23 02 32 23 02 52 43 12 32 33 0
P 4 2 3 03 03 83 33 23 93 13 03 83 02 93 83 23 23 93 13 03 83 13 03 83 33 33 93 13 13 8
M Q 38 26 26 33 29 28 34 27 26 33 26 26 33 28 28 34 27 26 33 27 26 33 29 29 34 27 27 33
R 4 0 2 82 83 53 13 03 62 92 83 52 82 73 53 03 03 62 82 83 52 82 83 53 13 03 62 92 83 6
P 5 6 3 63 64 44 04 04 63 73 64 43 63 54 44 03 94 63 73 64 43 73 64 44 14 04 73 83 74 5
LNQ 5 1 3 23 13 83 53 54 13 23 23 93 13 13 83 53 44 03 23 13 83 23 13 83 63 54 13 33 23 9
R 5 4 3 43 34 13 83 74 33 53 44 13 33 34 03 73 74 33 43 44 13 43 44 13 83 84 43 53 44 2
P 3 3 2 22 23 02 52 43 12 32 23 02 22 23 02 42 43 12 32 23 02 32 23 02 52 43 12 32 33 0
O Q 30 20 19 26 22 21 27 20 20 26 19 19 26 21 21 27 20 19 26 20 19 26 22 21 27 20 20 26
R 3 2 2 12 02 82 32 22 92 12 12 82 12 02 82 32 22 92 12 12 82 12 12 82 32 32 92 22 12 8
Early detection approach using computed tomography screening (EDCTS).
Symptomatic tumour identification (STID) method.
aRow and column headings represent input variable identification codes corresponding to Table 1. Each figure within the table above represents a unique combination of input
variables with the six-letter combination of row and column headings corresponding to the ‘scenario code’ for that set of variables (see Figure 1 for further explanation of
scenario codes). Note that the STID costs per 5-year survivor do not change across variables A through I.
bAs a conservative estimate, this calculation assumes that the lung
cancer survivors live no longer than 5 years.
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